Cybin CEO to Present at Neuro Perspectives Conference

Cybin ( (TSE:CYBN) ) just unveiled an announcement.

Cybin announced that its CEO, Doug Drysdale, will participate in a virtual fireside chat at the H.C. Wainwright 6th Annual Neuro Perspectives Conference. This participation highlights Cybin’s ongoing efforts to engage with the broader neuropsychiatry community and underscores its commitment to addressing unmet mental health needs through innovative treatments.

The most recent analyst rating on (TSE:CYBN) stock is a Buy with a C$114.00 price target. To see the full list of analyst forecasts on Cybin stock, see the TSE:CYBN Stock Forecast page.

Spark’s Take on TSE:CYBN Stock

According to Spark, TipRanks’ AI Analyst, TSE:CYBN is a Underperform.

Cybin’s stock score is significantly impacted by its lack of revenue and continuous financial losses, resulting in a low valuation score. While technical indicators are neutral, positive corporate events indicate potential for future growth. However, current financial challenges remain the dominant concern.

To see Spark’s full report on TSE:CYBN stock, click here.

More about Cybin

Cybin is a clinical-stage neuropsychiatry company focused on revolutionizing mental healthcare by developing innovative next-generation treatment options. The company is working on treatments for major depressive disorder and generalized anxiety disorder, with operations in Canada, the United States, the United Kingdom, the Netherlands, and Ireland.

Technical Sentiment Signal: Hold

Current Market Cap: C$1.97M

See more insights into CYBN stock on TipRanks’ Stock Analysis page.